Achieve defensibility. Unlock robustness. Align with regulators.
From legacy Gold TD₅₀ values to robust Lhasa-derived TD₅₀ methodology, Lhasa Limited is now pleased to introduce a new commercial solution to achieve informed carcinogenicity assessments.
The release of LCDB Plus is an exciting development towards enabling access to the best available carcinogenicity potency data and long-term study data.
The release of LCDB Plus introduces a new toolkit designed to support toxicologists and regulatory affairs specialists in conducting carcinogenicity assessments, including key workflows such as ICH M7 Class 1 impurity classification.
The comprehensive tool offers innovative functionality to apply the bespoke Lhasa Limited TD₅₀ methodology to your datasets, and an expansive dataset that provides access to 127% more carcinogenicity data than its predecessor.
Achieve a new standard in carcinogenicity decision-making
Reliability remains a primary challenge in the assessment of carcinogenicity studies, both for regulatory submissions and internal research.
Without a transparent, peer-reviewed foundation for data identification and TD₅₀ calculations, assessments remain vulnerable to scrutiny and delays.
Lhasa Limited is excited to introduce LCDB Plus 2026.1.0, providing members with data and tools to support more consistent evaluations.
- Facilitate informed decision making – uncover more than 4000 new carcinogenicity data structures.
- Ensure confident compliance – generate defensible and consistent TD₅₀ values for proprietary compounds.
- Demonstrate robust assessment – easily view the most sensitive tumour sites from the most sensitive species from the most robust study, and access enhanced reliability grading to assess studies.
All data available within LCDB Plus has been peer-reviewed by Lhasa scientists.
Together, the newly available data, reliability scoring, and TD₅₀ calculation functionality provide transparency and traceability to the decision-making process backed by an accepted framework.
Achieve defensibility with LCDB Plus!
The History of LCDB
The Lhasa Carcinogenicity Database (LCDB) holds a longstanding reputation for regulatory-aligned TD₅₀ values (lifetime dose at which tumours would be observed in 50% of animals) calculated in line with the CPDB Gold TD₅₀ values by Lois Gold and her team.
The Lhasa Carcinogenicity Database (LCDB) was officially released in 2016, founded on the retired Carcinogenic Potency Database (CPDB), which ceased updates in 2007. Both resources remain a vital source of long-term carcinogenicity study data particularly for the generation of acceptable limits as part of chemical risk assessments.
In 2026, Lhasa Limited is pleased to introduce LCDB Plus, building on this established foundation. The new platform, LCDB Plus, offers enhanced support for demonstrating robust and defensible assessment decisions.
How does LCDB Plus differ from the original CPDB and Lhasa Carcinogenicity Database?
- Over twice as much carcinogenicity data, expertly curated by Scientists at Lhasa Limited (LCDB Plus database contains data for an additional 2251 structures).
- A TD50 calculator to support risk assessments.
- Enhanced support to assist with confident decision-making and expert review.
- Advanced reliability scoring result, including context on the quality of the result and original generation or source of data.
- Reporting output functionality.
LCDB plus provides judgment on the relevance of data to demonstrate sound assessment, building on the foundation provided by CPDB and LCDB.
Unlock robustness with LCDB Plus.
The standard version of LCDB will continue to be freely available to all users, maintaining open access to essential scientific data.
All current users of LCDB will receive further communications to instruct them on how to access the commercial tool, LCDB Plus, where suitable.
We’re pleased to inform members of Sarah and Derek, Vitic, or Acrostic of their complimentary access to LCDB Plus.
How to implement LCDB Plus into your workflow
The release of LCDB Plus is an exciting addition to the support available for accurate and cost-effective carcinogenicity, in silico mutagenicity and nitrosamine assessments.
Through three different pathways, LCDB Plus can transform complex data into regulatory-ready outputs. Rapidly identify known carcinogens (or similar compounds), expertly calculate TD50 values, and simply pinpoint the most robust studies for dose-response modelling.
Embedding LCDB Plus offers a standardised approach to your workflow ensuring assessments are built to align with regulatory expectations.
By bridging the gap between raw TD50 values and regulatory-ready assessments, LCDB Plus provides users with the confidence to navigate the complexities of ICH M7 and beyond.
Align with regulators using LCDB Plus.
Deepen your understanding of LCDB Plus and Lhasa TD50 methodology in our webinar:
Senior Scientist, David Ponting, and Application Scientist, Jessica Halliday, will discuss leveraging carcinogenicity data alongside industry expert and Vice President at Procter & Gamble, Susan Felter, in a free-to-attend webinar on 29th April 2026. For more information or to register for the event, please visit our events page.